torcetrapib
Sign in to saveTorcetrapib (CP-529,414, Pfizer) was a drug being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease. Its development was halted in 2006 when phase III studies showed excessive all-cause mortality in the treatment group receiving a combination of atorvastatin (Lipitor) and torcetrapib.
Article
10 sectionsContents
- Medical uses
- Mechanism
- Development
- Clinical trials
- Early termination of study
- Synthesis
- See also
- References
- Notes
- External links
{{chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 461752029 | ImageFile = Torcetrapib.svg | ImageSize = | PIN = Ethyl (2R,4S)-4-({[3,5-bis(trifluoromethyl)phenyl]methyl}(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate | OtherNames =
| Section1 =